Gyre Therapeutics has demonstrated substantial progress through the first three quarters of FY2025, according to a report by Noble Capital Markets Senior Vice President and Equity Research Analyst Robert LeBoyer. The company reported continued sales growth from two recently launched products while advancing its clinical pipeline with significant developments for its lead drug candidate Hydronidone.
The company submitted an application for Hydronidone approval in China, marking a critical milestone in its global expansion strategy. Phase 3 clinical trial data for Hydronidone in chronic hepatitis B-associated fibrosis successfully met its primary endpoint of fibrosis regression, providing strong scientific validation for the treatment's efficacy. This data supports the company's NMPA filing planned for the third quarter of 2025.
With Breakthrough Therapy Designation already secured, regulatory approval for Hydronidone is anticipated in the second half of 2026, followed by commercial launch in FY2027. The company has also initiated a U.S. Phase 2 trial for Hydronidone, expanding its clinical development program across multiple markets. This dual-track approach demonstrates Gyre Therapeutics' commitment to addressing liver fibrosis treatment needs globally.
Concurrently, Gyre Therapeutics strengthened its leadership team by appointing Dr. Han Ying, a board member since January 2025, as Chief Executive Officer. The company's strategy builds on extensive experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis, providing a solid scientific foundation for its development programs.
In China, through its indirect controlling interest in Gyre Pharmaceuticals, the company is advancing a broad pipeline that includes therapeutic expansions of ETUAR(R) and development programs for F573, F528, and F230. This diversified approach positions Gyre Therapeutics as a significant player in the liver disease treatment landscape, with multiple assets progressing through various stages of development.
The progress reported by Gyre Therapeutics represents important advancements in liver fibrosis treatment, particularly for conditions like metabolic dysfunction-associated steatohepatitis (MASH) and chronic hepatitis B-induced fibrosis. These developments could potentially address significant unmet medical needs in hepatology and provide new treatment options for patients suffering from progressive liver diseases.
